Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the “miraculous” sodium-glucose co-transporter-2 inhibitors? Author’s reply by Terlecki, Michał et al.
1050 w w w . j o u r n a l s . v i a m e d i c a . p l / k a r d i o l o g i a _ p o l s k a
Correspondence to:
Prof. Marek Rajzer, MD, PhD,






Jakubowskiego 2,  
30–688 Kraków, Poland,
phone: +48 12 400 21 50, 
e-mail:  
marek.rajzer@uj.edu.pl
Copyright by the Author(s), 
2021
Kardiol Pol. 2021; 








  L E T T E R  T O  T H E  E D I T O R
Cardiovascular drug therapy and surrogate COVID-19 
outcomes: which is the impact of the “miraculous” sodium- 
-glucose co-transporter-2 inhibitors? Author’s reply
Michał Terlecki1, Wiktoria Wojciechowska1, Marek Klocek1, Michał Kania2, Maciej Małecki2,  
Tomasz Grodzicki3, Marek Rajzer1
1Department of Cardiology, Interventional Electrocardiology and Arterial Hypertension, Jagiellonian University Medical College, Kraków, Poland
2Department of Metabolic Diseases and Diabetology, Jagiellonian University Medical College, Kraków, Poland  
3Department of Internal Diseases and Geriatrics, Jagiellonian University Medical College, Kraków, Poland 
We would like to thank for the interest in our 
article. It has been confirmed in numerous 
studies that COVID-19 can lead to increased 
risk of a poor outcome, which is particularly 
expressed in patients with older age and 
co-existing cardiometabolic comorbidities [1]. 
We confirmed in our study that older age, type 
2 diabetes mellitus (DM), and heart failure were 
associated with worse in-hospital prognosis in 
patients hospitalized for COVID-19 [2]. 
We must admit that still there is a lack of 
specific therapy for COVID-19, despite the fact 
that numerous drugs have been studied. Since 
the beginning of the pandemic, the safety and 
efficacy of drugs dedicated to patients with 
cardiometabolic comorbidities have attracted 
interest. In our analysis, we confirmed that in 
patients hospitalized for COVID-19, prior treat-
ment with renin-angiotensin system blockers, 
statins, antiplatelet drugs, or beta-blockers was 
associated with a significant decrease in the 
odds of in-hospital death [2], however, due to 
the observational nature of the study, it does 
not prove the causal association. 
During several months of the pandemic, we 
have witnessed the change in the treatment 
standards of COVID-19 which have resulted 
in lower rates of complications (i.e. low-mo-
lecular-weight heparin in the prevention of 
thromboembolic events, steroids in patients 
requiring oxygen therapy, etc.). However, there 
is still a profound need to improve the stand-
ard of care in order to achieve faster and more 
complete recovery with an additional reduction 
of cases with fatal outcomes. 
We agree with Patoulias et al. that theoreti-
cally there might be a place for sodium-glucose 
co-transporter-2 (SGLT-2) inhibitors in the 
management of patients with COVID-19 [3]. 
SGLT-2 inhibitors are not only antidiabetic 
drugs but it has been proven that this group 
improves prognosis in populations similar to 
those at risk for COVID-19 worse outcome, i.e. 
patients with DM and in subjects with heart 
failure, chronic kidney disease, and atheroscle-
rotic cardiovascular disease [1, 4]. Treatment 
using SGLT-2 inhibitors is recommended by 
the latest 2021 Acute and Chronic Heart Failure 
Guidelines of the European Society of Cardiolo-
gy. Therefore, investigation of the efficacy and 
safety profile of these agents in patients with 
COVID-19 is warranted.
In our study, we analyzed clinical data from 
1729 patients. In this cohort, there were only 
26 patients (1.5% of the entire cohort) with prior 
treatment with SGLT-2 inhibitors. We must ac-
knowledge that it is insufficient to draw reliable 
conclusions. However, currently, we have avail-
able data of a larger group, i.e., 3391 patients 
hospitalized in our hospital for COVID-19. In this 
cohort, there were 65 patients (1.9%) treated 
with SGLT-2 inhibitors. In this group: 60 (92.3%) 
patients had DM, 9 (13.8%) had heart failure, 
13 (30.0%) had ischemic heart disease, and 
2 (3.1%) had chronic kidney disease. 
If we take into consideration the highly ben-
eficial impact of SGLT-2 inhibitors in patients 
with pre-existing cardiometabolic disorders, we 
must acknowledge that the prescription rate of 
these drugs in real life was lower than should 
have been expected. Of note, a low proportion 
of patients with diabetes on SGLT-2 inhibitors 
should be attributed mainly to a very limited 
reimbursement of these drugs in Poland, thus, 
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most type 2 diabetes patients have to pay for them out 
of pocket. At the beginning of the pandemic there was 
a concern about the safety profile of SGLT-2 inhibitors 
in patients with COVID-19, however, currently, there are 
data confirming their satisfactory safety profile in patients 
infected with SARS-CoV-2 [5]. 
In our cohort, we observed better outcomes among pa-
tients treated with SGLT-2 inhibitors (n = 65), as compared 
to non-treated (n = 3326). There were no in-hospital deaths 
in patients treated with SGLT-2, while in the rest of the co-
hort 354 (10.4%) patients died. We found lower frequency 
of need for mechanical ventilation (2 [0.1%] vs 351 [10.3%]; 
P = 0.027) in patients treated with SGLT-2 inhibitors. There 
was no significant difference in the need for intensive care 
unit hospitalization between SGLT-2 inhibitors users and 
non-users (5 [0.2%] vs 402 [11.8%]; P = 0.19). The low num-
ber of patients treated by SGLT2 inhibitors, the retrospec-
tive, observational nature of our analysis makes it prone to 
typical methodological problems, for example, selection 
bias related to higher eGFR among SGLT2 inhibitor users 
due to the SPC details in 2020 and beginning of 2021. Thus, 
the presented results should be treated with caution. 
However, looking at our results, we should at least 
consider the continuation of SGLT-2 inhibitors in subjects 
with pre-existing indications for those medications. The 
mechanism of SGLT-2 inhibitor’s action, the results of prior 
studies, and our findings indicate that further exploration 
is needed to fully establish the role of SGLT-2 inhibitors on 
COVID-19 course and outcome. 
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